Tocilizumab for giant cell arteritis: what is optimal?

Kaymakci, Mahmut; Warrington, Kenneth J.

doi:10.55563/clinexprheumatol/u5tnbs

Cited by 2 publications

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a study by Matza et al, TCZ therapy led to longterm remission and allowed for GC discontinuation in most patients, while maintaining a satisfactory safety profile (33). As the efficacy of TCZ has been well-established, recent literature has predominantly focused on determining the optimal duration of immunosuppressive and steroid therapy after achieving complete disease remission and subsequent tapering strategies, which remain an unmet need (34). A North American study by Samec et al followed a large cohort of GCA patients treated with TCZ for an extended period and observed a relapse rate exceeding 50% after abrupt discontinuation following a median treatment duration of 16.8 months ( 35).…”

Section: Gca/tak Treatment Updatementioning

confidence: 99%

Systemic vasculitis: one year in review 2024

Treppo,

Monti,

Delvino

et al. 2024

Clinical and Experimental Rheumatology

View full text Add to dashboard Cite

show abstract

Section: Gca/tak Treatment Updatementioning

confidence: 99%

Systemic vasculitis: one year in review 2024

Treppo,

Monti,

Delvino

et al. 2024

Clinical and Experimental Rheumatology

View full text Add to dashboard Cite

show abstract

Autoimmune Inflammatory Rheumatic Diseases in the Elderly

Kardum,

Šimac,

Marović

2024

AAEE

View full text Add to dashboard Cite

Nowadays, the importance of healthy and active aging is increasingly recognized due to the growing number of older individuals in the population. Autoimmune inflammatory rheumatic diseases can affect people at any stage of life, significantly impacting both morbidity, mortality and overall quality of life. Rheumatologic conditions that develop later in life have distinct characteristics compared to those that manifest at a younger age. Practitioners need to be familiar with these differences in order to make a timely diagnosis. Often, the first symptoms in elderly patients are nonspecific, constitutional symptoms, which are easily overlooked. Since multiple comorbidities accompany older age, treatment regimens should be individually adjusted, taking into account that these patients are more susceptible to severe infections compared to younger patients. However, the right and effective treatment should be provided to all patients, regardless of age, helping them to have active, dignified, and fulfilling seniority. In this review, common rheumatologic diseases are described with their uniqueness regarding older age and treatment options that appear to be well tolerated, efficacious, and without significant side effects in this age group.

show abstract

Tocilizumab for giant cell arteritis: what is optimal?

Cited by 2 publications

References 27 publications

Systemic vasculitis: one year in review 2024

Systemic vasculitis: one year in review 2024

Autoimmune Inflammatory Rheumatic Diseases in the Elderly

Contact Info

Product

Resources

About